Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry

K.I.E. Ibragimova, S.M.E. Geurts, S. Croes, F. Erdkamp, J.B. Heijns, J. Tol, B.E.P.J. Vriens, K.N.A. Aaldering, M.W. Dercksen, M.J.A.E. Pepels, N.A.J.B. Peters, L. van de Winkel, D.J.P. Tilli, I.J.H. Vriens, M. de Boer, V.C.G. Tjan-Heijnen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)571-581
Number of pages11
JournalBreast Cancer Research and Treatment
Volume188
Issue number2
DOIs
Publication statusPublished - 1 Jul 2021

Keywords

  • Breast neoplasms
  • Survival
  • Metastatic breast cancer
  • HER2-positive disease
  • Pertuzumab
  • T-DM1

Cite this